Back to top
more

USANA Health Sciences (USNA)

(Delayed Data from NYSE)

$43.14 USD

43.14
111,811

-0.56 (-1.28%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $43.15 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates

USANA Health (USNA) delivered earnings and revenue surprises of 67.31% and 6.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Q3 Earnings Miss Estimates

USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: USANA Health Sciences (USNA) Q3 Earnings Expected to Decline

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

USNA or STVN: Which Is the Better Value Stock Right Now?

USNA vs. STVN: Which Stock Is the Better Value Option?

USNA vs. ZTS: Which Stock Is the Better Value Option?

USNA vs. ZTS: Which Stock Is the Better Value Option?

USNA vs. ZTS: Which Stock Should Value Investors Buy Now?

USNA vs. ZTS: Which Stock Is the Better Value Option?

USNA or ZTS: Which Is the Better Value Stock Right Now?

USNA vs. ZTS: Which Stock Is the Better Value Option?

USANA Health Sciences (USNA) Tops Q2 Earnings and Revenue Estimates

USANA Health (USNA) delivered earnings and revenue surprises of 27.14% and 5.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About USANA Health (USNA) Rating Upgrade to Buy

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

USANA Health Sciences (USNA) Q2 Earnings and Revenues Lag Estimates

USANA Health (USNA) delivered earnings and revenue surprises of -4.76% and 0.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

USANA Health Sciences (USNA) Beats Q1 Earnings and Revenue Estimates

USANA Health (USNA) delivered earnings and revenue surprises of 0.88% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for USANA Health Sciences (USNA) This Earnings Season?

USANA Health Sciences (USNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

USANA Health Sciences (USNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

USANA Health (USNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: USANA Health Sciences (USNA) Q4 Earnings Expected to Decline

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

USANA Health Sciences (USNA) Q3 Earnings and Revenues Surpass Estimates

USANA Health (USNA) delivered earnings and revenue surprises of 4.62% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for September 29th

AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.

Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y

Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.

USANA Health Sciences (USNA) Beats Q2 Earnings Estimates

USANA Health (USNA) delivered earnings and revenue surprises of 5.06% and -0.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?